TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* no history of spontaneous puberty~* clinical hypogonadism~* infantile testes (\< 3 ml)~* no reproductive hormone therapy except testosterone~* Complete absence of normal LH pulses during 12-hour baseline frequent blood sampling and serum testosterone \< 100 ng/dl~* Normal testing of the anterior pituitary gland~* Negative MRI of the hypothalamic-pituitary area~Exclusion Criteria~* Prior therapy with gonadotropins (FSH, hCG, or GnRH)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (FSH) (Type: EXPERIMENTAL): Patients in Group 1 will receive subcutaneous follicle stimulating hormone (FSH) injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive gonadotropin releasing hormone (GnRH) therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.
- Group 2 (GnRH) (Type: ACTIVE_COMPARATOR): Patients in Group 2 will receive gonadotropin releasing hormone (GnRH) therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will not receive prior FSH administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Two Dose Regimens of Nifedipine for the Management of Preterm Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All pregnant women diagnosed with preterm labor defined as regular contractions associated with cervical change between 24 and 34 weeks of gestation~Exclusion Criteria:~* Multiple pregnancy~* Preterm rupture of membranes~* Congenital fetal malformations~* IUGR (intra uterine growth restriction)~* Previous tocolysis in this pregnancy~* Chorioamnionitis~* Cervical dilation \> 4 cms~* Maternal medical conditions such as renal insufficiency, hepatic insufficiency, or myasthenia gravis~* Non-reassuring fetal heart rate~* Maternal hypotension, defined as a blood pressure \< 90/50 mmHg

- Gender: FEMALE
- Minimum Age: 17 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: OTHER): High dose Nifedpine arm
- B (Type: OTHER): Low dose Nifedipine arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Extended-Release Melatonin in Patients With Rapid Eye Movement Sleep Behavior Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with Parkinson's disease and rapid eye movement sleep behavior disorder.~* Patient registered to Parkinson's disease database of Mayo Clinic Florida.~Exclusion Criteria:~* Patients who are using other sleep aids or medications (Clonazepam).~* Patients who are not willing to undertake 1 week of washout period.~* Patients who do not sign a consent for research.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immediate Release Melatonin, Then Extended Release Melatonin (Type: EXPERIMENTAL): Subjects will receive immediate release melatonin 5 mg orally at 9 pm every night for 4 weeks. After a washout period of 2 weeks, they then receive extended release melatonin 5 mg orally at 9 pm every night for 4 weeks.
- Extended Release Melatonin, Then Immediate Release Melatonin (Type: EXPERIMENTAL): Subjects will receive extended release melatonin 5 mg orally at 9 pm every night for 4 weeks. After a washout period of 2 weeks, they then receive immediate release melatonin 5 mg orally at 9 pm every night for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed extensive-stage SCLC~* Disease control after the first line platinum/etoposide treatment~* ECOG performance status of 0 or 1~* Measurable disease according to RECIST Version 1.1 criteria~* Adequate bone marrow, liver, and renal function.~* Formalin Fixed Paraffin Embedded (FFPE) or frozen tumor tissue material must be available.~* Resolution of any toxic effects of prior therapy according to NCI CTCAE, v 4.0~* Full recovery from significant complications of the surgery~* If childbearing age, use of double-barrier contraceptive measures, oral or abstaining from sexual intercourse during the study and up to 90 days after the last dose of chemotherapy~* Negative pregnancy test within 72 hours prior to the initiation of study treatment, if of childbearing potential~* Signed informed consent prior to beginning protocol specific procedures~* Patients must be available for treatment and follow-up~Exclusion Criteria:~* Previous therapies with Tivantinib or other known c-MET inhibitor~* Radiotherapy for target lesions and major surgical procedure within 4 weeks, prior to the inclusion in the study~* Palliative radiotherapy within 2 weeks prior to the inclusion in the study~* History of malignancy in the past five years, excluding basal cell the cervix, prostate cancer with a value of prostate-specific antigen \<0.2 ng / mL~* History of cardiac disease~* Known human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infections~* Pregnant or lactating women or childbearing/reproductive potential not using adequate contraception~* Need for breastfeeding during or within 12 weeks of completion of the study~* Gastrointestinal disorders that may interfere with the absorption of Tivantinib~* Inability or unwillingness to swallow the complete doses of Tivantinib~* Any known contraindication to treatment and other significant comorbid conditions which could jeopardize participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARQ-197 (Type: EXPERIMENTAL): ARQ-197 360 mg twice/day by mouth (PO), with meals, continuously as maintenance treatment until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Non-invasive Risk Stratification of CR AMN/SSP

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Individuals capable and willing of proving satisfactory informed consent~* Individuals with colonic lesions larger than 20mm~* Individuals diagnosed with laterally spreading or sessile polyp morphology~* Individuals schedules for screening colonoscopy and with no prior history of CRC~* Ability and willingness to collect stool sample at home~* Ability and willingness to undergo venepuncture procedure~Exclusion Criteria:~* Individuals not able or unwilling to provide informed consent~* Individuals less than 18 year of age~* Individuals who undergo an incomplete colonoscopy or resection, which raises doubt as to the status of the colon (post-hoc exclusion)~* Individuals with a prior history of CRC~* Individuals with a history of Irritable Bowel Disease (IBD), hereditary nonpolyposis colorectal cancer (HNPCC) or Familial adenomatous polyposis (FAP)~* Individuals with bleeding diathesis~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Normal subjects (Type: None): blood or stool samples will be collected from people referred for screening colonoscopy
- Colorectal cancer (Type: None): blood or stool samples will be collected from people with colorectal cancer detected at colonoscopy or resection
- Polyps <10mm and no high risk features (Type: None): blood or stool samples will be collected from people with no polyps or low risk polyps (\<10mm, no villous component or dysplasia) detected at colonoscopy
- Advanced Mucosal Neoplasia (Type: None): blood or stool samples will be collected from people with AMN detected at resection
- Sessile Serrated Adenoma (Type: None): blood or stool samples will be collected from people with SSP detected at resection
- non-colorectal neoplastic disease (Type: None): Participants with disease that is not colorectal neoplasia. Analysis of this cohort is not a primary endpoint but the investigators will report assay positivity in this group on an opportunistic basis. This cohort will include patients diagnosed with, for example, inflammatory bowel disease or extracolonic cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Interest of the Confocal Microscope in the Diagnosis of Epidermoid Carcinoma of the Vulva and Their Precursors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age = 18 years, Female~* Patient seen in consultation in the service of gynecology obstetrics, and, of dermatology of the Bow presenting during the medical examination one or several suspicious-looking vulvar hurts, suggestive of hurts of VIN or of carcinoma epidermoid vulvar~* Membership health secure~* Informed consent and paper of the obtained patient~Exclusion Criteria:~* Patient having already received a local treatment(processing) for hurts of VIN~* Pregnant Woman~* Patient under guardianship~* Not signature of the written consent and/or mental deficiency of the subject making its participation on approval impossible

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- description (Type: OTHER): photographies and biopsy on normal area

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Cardiac Lesions Angiogenesis by 68Ga-NODAGA-RGD Cardiac PET

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients with acute infarction or patients with acute infarction requiring reperfusion treatment or patients with chronic ischemic occlusion~* Karnofsky ≥ 80%~* signed informed consent~Exclusion Criteria:~* pregnancy, breastfeeding~* claustrophobia~* contra-indication to adenosine administration~* lack of discernment to sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- acute infarction (Type: OTHER): patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT at 1, 4 and 12 weeks after cardiac event
- acute infarction requiring reperfusion (Type: OTHER): patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT at 1, 4 and 12 weeks after cardiac event
- chronic ischemic occlusion (Type: OTHER): patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT before and 2 months after reperfusion treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2~ 2. Pathology report confirming adenocarcinoma of the prostate~ 3. Risk of lymph node metastasis less than 10% as defined by the Partin tables~ 4. Tumor visible on magnetic resonance imaging (MRI)~ 5. No prior surgery, radiation, or chemotherapy for prostate cancer.~ 6. Age greater than 18 y/o and less than 90 years old.~EXCLUSION CRITERIA:~1. Cognitively impaired patients who cannot give informed consent.~2. Patients with metastatic disease.~3. Contraindication to biopsy~   * Bleeding disorder~  * Prothrombin time (PT)/Partial Thromboplastin Time (PTT) greater than or equal to 1.5 times the upper limit of normal~  * Platelets less than or equal to 50K~  * Artificial heart valve~4. Contraindication to magnetic resonance imaging (MRI)~   * Patients weighing greater than 136 kgs (weight limit for the scanner tables)~  * Allergy to MR contrast agent~  * Patients with pacemakers, cerebral aneurysm clips, shrapnel injury or implantable electronic devices.~5. Pre-existing and active prostatitis or proctitis~6. Other medical conditions deemed by the principal investigator (PI) or associates to make the patient ineligible for protocol investigations, procedures, and high-dose external beam radiotherapy.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Radiation Therapy (Type: EXPERIMENTAL): Radiation to tumor area as per protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Intravitreal Injections of Melphalan for Retinoblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Retinoblastoma that has not responded to chemotherapy~* Retinoblastoma that has vitreal seeding~Exclusion Criteria:~* previous failure of IVit Melphalan

- Gender: ALL
- Minimum Age: None
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- IVit Treatment group (Type: EXPERIMENTAL): Intravitreal injections of Melphalan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women between 18 and 50 years old~* Cutaneous ulcers of more than two weeks of evolution~* Positive parasitological diagnosis for CL~* Patients that voluntarily agree to participate in the study and sign the informed consent.~* Disposition to attend all the visits punctually (initial, treatment and follow-up)~* Acceptation of not using any other treatment for CL while in the study~Exclusion Criteria:~* Pregnant women~* Presence of any condition or disease that compromises the patient immunologically (i.e. diabetes, cancer, etc.) or, any other, that, based on the judgment of the researcher, could alter the course of CL.~* Diffuse CL or more than five active lesions.~* Mucocutaneous leishmaniasis (no lesion must be located less than 2 cm from the nasal, uro-genital, and/or anal mucous membranes or from the edge of the lips).~* Visceral leishmaniasis~* Complete or incomplete treatment with antimony compounds in the last three months.~* Patients with history of hepatic, renal or cardiovascular disease.~* Mentally or neurologically disabled patients that are considered not fit to approve their participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Thyroid Hormones in Critically Ill Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent~* Age of less than 12 months and less than or equal to 18~* Patient must weigh greater than 10 kgs.~* Patients must require vasoactive infusions and/or mechanical ventilation.~* Patients must be enrolled within 24 hours of meeting eligibility.~Exclusion Criteria:~* Patient with known or presumed pre-existing thyroid disease will be excluded~* Patients who receive thyroid supplementation will be excluded~* Patients with known or presumed hypothalamic and/or pituitary dysfunction that have thyroid hormone concentration abnormalities not related to an acute illness.~* Patients who are intubated for airway protection only.~* Patients intubated for neuromuscular disease~* Pregnant patients.~* Patients receiving amiodarone supplementation~* Patients who received blood product transfusions equaling more than 1/2 of their blood volume.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Patients who are receiving vasoactive medications and/or are mechanically ventilated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pragmatic Prehospital Group O Whole Blood Early Resuscitation Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Injured patients being transport via an air medical service with hypotension (SBP =/\< 90mmHg with tachycardia \>108 OR SBP=/\<70 without the tachycardia requirement)~Exclusion Criteria:~Age \< 18 or \> 89 years~Isolated fall from standing injury mechanism~Brain matter exposed or penetrating brain injury (GSW)~CPR \> 5 mins with out ROSC~Isolated burns without evidence of traumatic injury~Isolated Drowning or Hanging~No Intravenous or Intraosseous access~Known prisoner or known pregnancy~Referral Hospital Admission~Wearing No PPOWER bracelet~Objection to study voiced by subject or family at scene

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- LTLR-WB (Type: EXPERIMENTAL): Receiving 2 units of low titer, leucocyte reduced, platelet replete whole blood initiated in the prehospital setting during air medical transport and continued (up to 6 units of whole blood followed by standard component resuscitation) thru the early in-hospital phase of care
- Standard Care (Type: NO_INTERVENTION): Receiving standard prehospital air medical care and standard of care component (1:1:1) trauma resuscitation thru the early in-hospital phase of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women ≥ 18 years of age~* Diagnosis of definite oGVHD using the International Chronic Ocular GVHD Consensus Group Revised Diagnostic criteria in at least one eye.~* Ocular Discomfort score ≥ 3~* Validated Bulbar Redness score ≥ 40 in both eyes~* Subjects who are capable and willing to provide informed consent and follow study instructions~* Intraocular pressure (IOP) ≥ 5 mmHg and ≤22 mmHg in each eye~* Women who are not pregnant or lactating or post-menopausal or have undergone a sterilization procedure~Exclusion Criteria:~* Allergic to brimonidine or any similar products, or excipients of brimonidine~* Currently receiving any brimonidine or other treatment for glaucoma~* Receiving or have received any investigational drug or device within 30 days of screening~* Current use of contact lenses 14 days prior to screening~* Active ocular infection or ocular allergies~* Any history of eyelid surgery or ocular surgery within the past 3 months~* Corneal epithelial defect larger than 1 mm (squared) in either eye~* Received corticosteroid-containing eye drops within 14 days prior to screening or planned use during the study~* Any change in corticosteroid-containing eye drops, systemic corticosteroids/immunosuppressives, topical ocular antibiotics, cyclosporine ophthalmic emulsion 0.05% (Restasis®), cyclosporine ophthalmic solution 0.09% (Cequa®) or lifitegrast ophthalmic solution 5% (Xiidra®), or autologous serum tears within 30 days prior to screening or planned change during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OCU-300 (Type: EXPERIMENTAL): Brimonidine Tartrate Nanoemulsion Eye Drops 0.18% given 2 times a day for 12 weeks.
- Placebos (Type: PLACEBO_COMPARATOR): Placebo - Ophthalmic buffered saline Eye Drops given 2 times a day for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy